REG - Hikma Pharmaceutical - Director/PDMR Shareholding <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

05/12/2016 12:35

RNS Number : 9861Q
Hikma Pharmaceuticals Plc
05 December 2016
Notification and public disclosure of transactions by persons discharging managerial responsibilities
The attached individual notification made under article 19.1 of the Market Abuse Regulation ("MAR") relates to the purchase by HMS Holdings SAL of Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive, and the Vice Chairman shareholders in HMS Holdings SAL. This announcement is made in accordance with article 19.3 of MAR.
Said Darwazah
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Said Darwazah
2
Reason for the notification
a)
Position/status
Chairman and Chief Executive Officer / PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each
ID Code: GB00B0LCW083
b)
Nature of the transaction
Acquisition by HMS Holdings SAL of 350,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive is a shareholder in HMS Holdings SAL with an equity interest of 29.16%.
c)
Price(s) and volume(s)
Price(s): 16.74
Volume(s): 350,000
d)
Aggregated information
Aggregated volume: 350,000
Price: 16.74
e)
Date of the transaction
2 December 2016
f)
Place of the transaction
London Stock Exchange (XLON)
Mazen Darwazah
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mazen Darwazah
2
Reason for the notification
a)
Position/status
Executive Vice Chairman / PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each
ID Code: GB00B0LCW083
b)
Nature of the transaction
Acquisition by HMS Holdings SAL of 350,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Vice Chairman is a shareholder in HMS Holdings SAL with an equity interest of 29.16%.
c)
Price(s) and volume(s)
Price(s): 16.74
Volume(s): 350,000
d)
Aggregated information
Aggregated volume: 350,000
Price: 16.74
e)
Date of the transaction
2 December 2016
f)
Place of the transaction
London Stock Exchange (XLON)
Peter Speirs, Company Secretary, Responsible for releasing this announcement
5 December 2016

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHBDBDDDXGBGLU